Re Agreement

NMT Group PLC
14 October 2002

14 October 2002





New Medical Technology Announces Global Supply Agreement with Roche



New Medical Technology Group PLC (NMT), the manufacturer of retractable devices
to prevent needlestick injury, announces today that it has signed a Global
Supply Agreement with Roche, one of the world's leading pharmaceutical companies
for the supply of its 1cc and 3cc automatic retractable safety syringes.  The
NMT Safety Syringe will be packaged alongside Roche's FUZEON(R) (enfuvirtide;
formerly known as T-20), a revolutionary new drug for the treatment of HIV.
Marketing authorisation applications for FUZEON(R) have been submitted in the
USA, EU, Canada and Switzerland.



It is anticipated that Fuzeon(R) will be commercially launched in Europe and the
US from early 2003.  Most patients will be using Fuzeon(R) either in their own
homes or at work, and it is therefore of paramount importance that patients are
supplied with an easy to use system that is equipped with a safety device
intended to reduce the possibility of a needlestick injury. The NMT Safety
Syringe will be used to draw up and mix the medication before actually being
injected by each patient.  The NMT Safety Syringe features automatic needle
retraction technology that is activated as the user fully depresses the plunger
at the completion of the injection process.  After having been automatically
retracted, the needle is safely stored in the barrel after use, thereby
virtually eliminating needlestick injuries.



Commenting on today's news, Roy Smith, Chief Executive of NMT, said:



 'I am delighted that we have reached agreement with Roche, one of the world's
leading pharmaceutical companies, for the supply of our retractable technology.
This agreement represents a highly significant milestone in the history of NMT
and provides us with further validation that our product is the leading edge
technology in the prevention of exposure to blood borne pathogens. Furthermore I
would wish to express my personal appreciation to our employees for their
support during this difficult period.



We have secured a contract, which I believe is the largest for retractable
syringes and this achievement should create the platform for further commercial
success. We look forward to a long and successful business relationship with
Roche.'





Enquiries:


NMT Group PLC

Roy Smith, Chief Executive Officer                                  01590 687901
Gerard Cassels Chief Financial Officer                              01506 445049

Financial Dynamics
Jonathan Birt/Fiona Noblet                                         020 7831 3113




                      This information is provided by RNS
            The company news service from the London Stock Exchange